Frankfurt - Delayed Quote EUR

Pharvaris N.V. (9EN.F)

14.30
+0.30
+(2.14%)
At close: May 15 at 9:55:01 PM GMT+2
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
0
0
0
0
0
Operating Expense
145,688.17
145,688.17
96,913.62
86,714.61
54,138.63
Operating Income
-145,688.17
-145,688.17
-96,913.62
-86,714.61
-54,138.63
Net Non Operating Interest Income Expense
5,422.55
5,422.55
204.02
-39.25
-282.51
Other Income Expense
7,869.11
7,869.11
-3,116.66
11,100.39
11,760.47
Pretax Income
-132,396.50
-132,396.50
-99,826.26
-75,653.47
-42,660.66
Tax Provision
1,825.02
1,825.02
1,048.81
679.09
70.12
Net Income Common Stockholders
-134,221.53
-134,221.53
-100,875.07
-76,332.56
-42,730.78
Diluted NI Available to Com Stockholders
-134,221.53
-134,221.53
-100,875.07
-76,332.56
-42,730.78
Basic EPS
-2.48
--
-2.63
-2.27
-1.40
Diluted EPS
-2.48
--
-2.63
-2.27
-1.40
Basic Average Shares
54,020.55
--
38,391.65
33,585.98
30,411.90
Diluted Average Shares
54,020.55
--
38,391.65
33,585.98
30,411.90
Total Expenses
145,688.17
145,688.17
96,913.62
86,714.61
54,138.63
Net Income from Continuing & Discontinued Operation
-134,221.53
-134,221.53
-100,875.07
-76,332.56
-42,730.78
Normalized Income
-140,060.41
-140,060.41
-98,562.50
-84,569.05
-51,551.13
Interest Expense
--
--
--
16.11
267.51
Net Interest Income
5,422.55
5,422.55
204.02
-39.25
-282.51
EBIT
-145,688.17
-145,688.17
-96,913.62
-86,714.61
-54,138.63
EBITDA
-145,418.61
-145,418.61
-96,656.07
-86,561.67
-54,061.26
Reconciled Depreciation
269.56
269.56
257.55
152.94
77.37
Net Income from Continuing Operation Net Minority Interest
-134,221.53
-134,221.53
-100,875.07
-76,332.56
-42,730.78
Total Unusual Items Excluding Goodwill
7,869.11
7,869.11
-3,116.66
11,100.39
11,760.47
Total Unusual Items
7,869.11
7,869.11
-3,116.66
11,100.39
11,760.47
Normalized EBITDA
-153,287.72
-153,287.72
-93,539.41
-97,662.06
-65,821.73
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
2,030.23
2,030.23
-804.10
2,863.90
2,940.12
12/31/2021 - 2/16/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

OCS Oculis Holding AG
18.30
+5.90%
 
NERV Minerva Neurosciences, Inc.
1.5550
-2.20%
 
LENZ LENZ Therapeutics, Inc.
27.34
-1.05%
 
KZIA Kazia Therapeutics Limited
3.4000
-3.00%
 
REPL Replimune Group, Inc.
7.23
+3.14%
 
PDSB PDS Biotechnology Corporation
1.3500
+3.05%
 
FBIO Fortress Biotech, Inc.
1.7800
+7.23%
 
OCUL Ocular Therapeutix, Inc.
7.17
+3.46%
 
SNDX Syndax Pharmaceuticals, Inc.
8.95
-3.56%
 
UNCY Unicycive Therapeutics, Inc.
0.5506
-1.38%